Across TCGA pan-cancer cohorts, OR2M3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR2M3 data layer compared with 9 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR2M3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2M3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
STAD, ESCA, and PAAD are the cancer types where OR2M3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.